Introduction
============

Liraglutide is a human glucagon-like peptide-1 receptor agonist (RA) approved for the treatment of adults with type 2 diabetes mellitus (T2DM) and more recently for weight management.[@b1-dmso-11-791],[@b2-dmso-11-791] In the randomized trials conducted for liraglutide 3.0 mg (Saxenda^®^; Novo Nordisk A/S, Copenhagen, Denmark) weight management indication, a twofold imbalance of breast neoplasms occurred. While the numbers were small, this imbalance was not seen in the development program for T2DM.[@b3-dmso-11-791] Most breast cancer (BC) cases were diagnosed during the first year of follow-up and occurred more frequently among women who lost more weight, potentially making discovery of the cancers more likely, suggesting detection bias.[@b4-dmso-11-791],[@b5-dmso-11-791] Nevertheless, these findings were sufficient to result in a concern that GLP-1 RAs might increase the risk of BC.[@b6-dmso-11-791] Hicks et al have also presented a hypothesis relating to a possible biological effect.[@b7-dmso-11-791] Preclinical studies have shown that GLP-1 receptors are located on normal breast tissue[@b8-dmso-11-791] and suggest that GLP-1 analogs could promote tumor growth via fibroblast growth factor 7.[@b9-dmso-11-791],[@b10-dmso-11-791] Given that both T2DM and obesity are also known risk factors for BC, evaluation of medications that may increase the risk of BC is warranted.[@b11-dmso-11-791]--[@b13-dmso-11-791] These concerns motivated the current investigation, taking advantage of an ongoing post-marketing safety study of liraglutide (1.2 mg and 1.8 mg) used for treatment of diabetes.

This study quantifies the relationship between liraglutide and BC relative to comparison groups using a new-user, active-comparator study design within a well-defined population of women from a US administrative health care database.[@b14-dmso-11-791]

Research design and methods
===========================

Study population and exposures
------------------------------

A prospective cohort study was conducted within the Optum Research Database, a large, geographically diverse population of commercial health insurance enrollees in the US. The study antidiabetic drugs (ADs) included liraglutide and comparator medications, including exenatide, metformin, pioglitazone, a sulfonylurea (SU; glyburide, glipizide, glimepiride), or a dipeptidyl peptidase-4 inhibitor (DPP-4i; sitagliptin, saxagliptin, linagliptin). Patients were women aged 18 years and over who initiated liraglutide or a comparator following at least 6 months of continuous health plan enrollment with complete medical and pharmacy benefits. Drug initiation was defined as an observed dispensing for a study AD, with the absence of a dispensing of that drug or drug class during the preceding baseline period of 6 months. Patients with any ICD ninth edition (ICD-9) diagnosis codes for malignant neoplasm of female breast *(*174.x) or personal history of malignant neoplasm of breast (V10.3) in the baseline period were excluded as prevalent cancers. This study was approved by the New England Institutional Review Board and Privacy Board.

Patients with eligible initiations were identified from 01 February 2010 to 30 November 2014. Due to changing prescribing patterns and composition of drugs in the US market, cohorts were assembled quarterly for 2010--2012 and annually for 2013--2014 (14 calendar blocks). Followup time began the day after the first eligible initiation and continued until the earliest of disenrollment from the health plan, the occurrence of BC, or the end of the study period (December 31, 2014).

Covariates and propensity score (PS) modeling
---------------------------------------------

PS matched analyses were conducted to balance baseline covariates characterizing demography, comorbidity, concomitant medications, and intensity of health care utilization. PSs were estimated separately for each of the seven comparison groups (five comparator drugs as well as for "all comparators" and "all comparators minus exenatide" \[to remove any GLP-1 RA effect\]).[@b15-dmso-11-791]--[@b17-dmso-11-791] Key covariates, including use of other ADs including insulin, are noted in [Table 1](#t1-dmso-11-791){ref-type="table"}. Because PSs balance only measured covariates and their correlates, missing or miss-measured covariates may allow for residual confounding.[@b18-dmso-11-791] Several hundred covariates were considered for the PS model to reduce the impact of potential residual confounding.[@b19-dmso-11-791]

Variables that were correlated with the exposures and likely to be correlated with BC were forced into the model to ensure that they contributed to the final PS estimates. Known risk factors for BC (eg, ductal carcinoma in situ, overweight/obesity), screening procedures, markers for diabetes severity, and variables representing baseline AD use were included. Additional predictors were selected with forward stepwise regression.

Within each of the 14 calendar blocks, initiators of liraglutide were PS matched 1:1 to initiators in each of the comparison groups.[@b20-dmso-11-791] Patients who did not match during one accrual time block but initiated that same drug or another study drug in a later accrual time block were again eligible for matching, and the PS was re-estimated using a 6-month baseline period prior to that initiation. Patients could enter into multiple matched cohorts but were allowed to match into each drug cohort pair only once. For logistical reasons, BC case status was determined prior to the PS estimation, but matching occurred without consideration of case status.

Outcome assessment
------------------

Potential claims-identified BC cases were initially identified by an algorithm developed by Setoguchi et al .[@b21-dmso-11-791] The algorithm required 2 or more days with claims with an ICD-9 code for malignant neoplasm of the breast (ICD-9 174.x) within 61 days of each other that were associated with inpatient, outpatient, or emergency room encounters. This algorithm had a high positive predictive value (PPV) within Medicare claims data (PPV 76.6%), but the population of the Optum study was younger and therefore was considered to be potentially at lower risk for BC.[@b22-dmso-11-791] Given that the validity of measurement of outcomes will generally decrease with decreasing frequency of occurrence[@b23-dmso-11-791] and the Setoguchi study also included in situ BCs which were not included in this study, an additional review of detailed chronological listings of claims for services and treatments (patient profiles) for each potential case of BC was included. An independent clinical consultant conducted claims review using patient profiles covering the period 3 months prior to the qualifying BC diagnosis to the end of a woman's follow-up data or the end of the study (December 31, 2014). The clinical reviewer considered the presence and timing of relevant procedures (eg, biopsies and mammograms), diagnoses, treatments (eg, chemotherapy, radiation, mastectomy), types of specialists associated with diagnoses (eg, oncologist), and general patterns of care to classify potential cases into one of the following three categories: New-onset (incident) BC (highly likely BC case occurring following study drug initiation date)BC with onset date likely prior to study cohort entry date (prevalent case)Not a case of BC (sufficient evidence to rule out BC)

For incident BC cases, the clinical reviewer also recorded the earliest date on which there was an indication that BC was present. Only incident cases were used in the analyses.

Statistical methods
-------------------

Baseline characteristics are provided for liraglutide initiators and "all comparators" combined. Because of the complexity of drug use patterns, several methods were used to separately quantify risks associated with starting liraglutide, being on liraglutide currently, and cumulative exposure. As the primary analysis, an analog to intention-to-treat (ITT) analysis of randomized trials was applied to quantify the risk associated with starting treatment, attributing all follow-up time to the initial exposure cohort. Incidence rates (BC cases per 100,000 person-years) were estimated as the number of patients with BC divided by the person-years of follow-up. Poisson regression models were used to estimate incidence rate ratios (RRs) and 95% CIs for liraglutide vs each comparator group. Generalized estimating equations (GEEs) were used to account for the paired nature of the data created by matching, except in cases when data were too sparse to support the GEE estimation.[@b24-dmso-11-791] In a latency analysis, person-time and BC cases from the first year of each patient's follow-up were excluded to focus on the probable period of any liraglutide effect on BC.

A time-on-drug (TOD) analysis was performed to evaluate the effect of recency of use of liraglutide. The dispensing date and days' supply (ie, a pharmacist-estimated number of days that a prescription is expected to last if taken according to the prescribing instructions) were used to categorize each person-day of follow-up into "current", "recent", and "past" use, for each study drug. "Current" use included the day after the dispensing date up through the end of the days' supply. A 31-day grace period was added to the end of days' supply to allow for variable adherence. "Current" use continued as long as new refill dispensings were observed before the grace period ended. Once the grace period expired, it was assumed the patient discontinued that drug. The next 31 days (person-time occurring between 32 and 62 days after "current" use) were considered as "recent" use. Person-time occurring after "recent" use was categorized as "past" use and persisted unless the patient re-started the same treatment, thereby re-entering the "current" use category. Because many patients switched and added AD therapies regularly, patients in matched pairs may have had use of both liraglutide and a comparator during follow-up. If BC was diagnosed while the patient was currently on liraglutide and had past use of the comparator, for example, the BC case and corresponding person-time were included in the incidence estimate for "current" liraglutide use and "past" comparator use. When patients had concurrent use of both drugs in the comparison, cases and person-time were included in "current" use for both drugs. Poisson regression was used to estimate the RRs and 95% CIs for "current", "recent", and "past" use of liraglutide vs the same "current-recent-past" category for comparators, adjusted by the logit of the PS to address confounding.

An additional TOD analysis quantified patients' cumulative time on liraglutide from cohort entry and compared the associated rate of BC within time unexposed to liraglutide (which was generally exposed to other ADs). For patients who initiated one of the other study drugs and later initiated liraglutide, cumulative exposure to liraglutide began at the time of that dispensing and subsequent person-time was no longer considered "liraglutide unexposed". RRs were estimated using Poisson regression modeling within categories of cumulative time (\<6 months, 6--18 months, and \>18 months) relative to all "liraglutide unexposed" time, and models were adjusted for the logit of the PS.

The potential for surveillance bias was considered by comparing frequency of mammography during follow-up for each exposure group. The timing of BC diagnosis relative to cohort entry was examined for each of the seven matched cohorts. In addition, the distribution of cases by age group was examined, relative to the distribution of patients overall.

Results
=======

Over the study period, 192,752 women were identified across all the drug cohorts. Of these, 4,202 (2.2%) had claims consistent with BC in the baseline period and were excluded from this analysis, leaving 188,550 women in the study. There were 1,009 algorithm-identified cases, of which 151 (15.0%) were consistent with prevalent BC, eight (0.8%) were determined to be non-cases, and 850 (84.2%) were clinical reviewer-confirmed incident BC cases ([Figure 1](#f1-dmso-11-791){ref-type="fig"}).

Among the matched liraglutide and "all comparator" initiators (n=17,880 in each cohort, [Figure 1](#f1-dmso-11-791){ref-type="fig"}), there were 85 and 94 confirmed cases, respectively. Substantial differences in the sizes of matched cohort pairs were due to variations in available comparators across study drugs.

After PS matching, the baseline characteristics were well matched in the liraglutide and "all comparator" pairs ([Table 1](#t1-dmso-11-791){ref-type="table"}) and all other comparator pairs (data not shown). In the matched cohorts, the proportion of cases across age groups was similar, except that the liraglutide cohort cases tended to have a higher proportion in the 60--64 years group and a lower proportion in 40--49 years ([Table S1](#SD8-dmso-11-791){ref-type="supplementary-material"}). For all cohorts, the distribution of cases was skewed toward the older ages, relative to the distribution of patients by age. For example, while 5.9% of the "all comparator" patients were age 65+ years, 11.7% of the cases were in that age group. A similar pattern was observed in the liraglutide cohort (6.1% of liraglutide patients were age 65+ years vs 10.6% of cases). Median lengths of followup were similar "within" matched drug cohorts, with some variation "across" matched sets ([Table 2](#t2-dmso-11-791){ref-type="table"}). Results for the ITT and TOD analyses are presented in [Figure 2](#f2-dmso-11-791){ref-type="fig"}. In the primary analysis (ITT), RRs ranged from a low of 0.90 for both the comparison with "all comparators" (95% CI: 0.67--1.21) and "all comparators excluding exenatide" (95% CI: 0.67--1.22) to a high of 1.46 (95% CI: 0.96--2.22) relative to exenatide.

Approximately 50% of all BC cases in the matched cohorts occurred during the first year of follow-up, leading to less precise estimates in the latency analysis. The observed RRs ranged from a low of 0.83 (95% CI: 0.55--1.26) for "all comparators excluding exenatide" to a high of 1.50 (95% CI: 0.87--2.58) for metformin. The RRs in the latency analyses were all the same or smaller and less precise, with the exception of the increase observed for the metformin comparison, from RR 1.10 (95% CI: 0.76--1.61) to 1.50 (95% CI: 0.87--2.58).

In the TOD analyses, RRs during "current" use ranged from a low of 0.95 (95% CI: 0.64--1.40) for SUs to a high of 1.63 (95% CI: 0.92--2.88) for pioglitazone. RRs for "recent" use (32--62 days after current use) were consistently lower than "current" use. RRs for "past" time followed no consistent pattern. The cumulative TOD analysis was performed only for the liraglutide vs "all comparator" matched cohorts. RRs were 0.79 (95% CI: 0.55--1.13) for \<6 months of liraglutide exposure, 1.03 (95% CI: 0.69--1.54) for 6--18 months of exposure, and 0.98 (95% CI: 0.55--1.76) for ≥18 months of exposure. Across all ITT and TOD analyses, all comparisons had 95% CIs that included the null.

Assessment of surveillance bias revealed that liraglutide and exenatide cohorts had more mammograms during follow-up than the other cohorts (mean of 0.78 \[SD 1.15\] and 0.84 \[SD 1.22\], respectively). In contrast, the SU cohort had a mean of 0.51 (SD 0.95). Within each matched cohort, the time to diagnosis was similar with the exception of the metformin cohort which had a substantially shorter median time to diagnosis (309 vs 415 days) and the DPP-4i cohort which had a longer median time (479 vs 339 days) ([Table 3](#t3-dmso-11-791){ref-type="table"}; also see [Figures S1](#SD1-dmso-11-791){ref-type="supplementary-material"}--[S7](#SD7-dmso-11-791){ref-type="supplementary-material"}).

Discussion
==========

Overall, these data are consistent with no association between the use of liraglutide and risk of incident BC across different comparators and several different analyses, similar to the findings of Hicks et al and the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial.[@b7-dmso-11-791],[@b25-dmso-11-791] Baseline differences between liraglutide initiators and those of other ADs were largely accounted for with the PS matching.

The motivation for this study was the observation of an imbalance in the reported proportion of BC cases in the early liraglutide weight management trials in which adjudicated BCs were reported in 17 (0.7%) of 2,379 liraglutide-treated women compared with three (0.2%) of 1,300 placebo-treated women.[@b3-dmso-11-791] Most cases were diagnosed during the first year of follow-up, which would likely include BCs that were preclinical at the time of study initiation; follow-up in general was limited (mean of 46 weeks, maximum of 160 weeks). The numbers included ductal carcinoma in situ (four liraglutide and one placebo).

A recently published observational study in the UK using the Clinical Practice Research Datalink compared BC incidence in initiators of GLP-1 RAs (exenatide, liraglutide, others) with initiators of DPP-4i.[@b7-dmso-11-791] No overall increased risk of BC associated with use of GLP-1 RAs was found (adjusted hazard ratio \[HR\] 1.40 (95% CI: 0.91--2.16). Findings were similar when liraglutide was the only GLP-1 RA compared to DPP-4i. While the study included 44,984 patients, the primary analysis involved only 498 patients using a GLP-1 RA and 2,422 patients using a DPP-4i. These findings were consistent with findings in the recently completed LEADER trial, comparing liraglutide with placebo. Patients were followed for up to 172 weeks (median, 86 weeks). In LEADER, a small number of malignant breast neoplasms were identified in both groups: 21 patients in the liraglutide group (1.3%, 0.33/100 person-years) and 20 patients in the placebo group (1.2%, 0.31/100 person-years, HR 1.06; 95% CI: 0.57--1.96).[@b25-dmso-11-791]

Several limitations should be considered when interpreting our study findings. Despite balance on a wide array of measurable baseline covariates, the potential for residual confounding by unmeasured factors remains. In particular, a patient's body mass may influence physicians' prescribing, particularly for antidiabetic medications which are known to be associated with additional weight loss benefits (eg, liraglutide). If body mass is sufficiently correlated with the included measured covariates, then residual confounding is unlikely, but this is not testable with the available data.

A substantial proportion of the BC cases in the current study were observed within the first year following study drug initiation, and many within the first 6 months. It is recognized that causative agents do not lead to cancers immediately after exposure and may manifest clinically only after several decades.[@b26-dmso-11-791] While it is possible that diabetic therapies might accelerate the development of a cancer already initiated, each of the pathways to clinically evident cancer requires time before the cancer reaches the point of detection.[@b27-dmso-11-791]

A latency analysis addressed the concern about inclusion of prevalent but undiagnosed cancers at the time of drug initiation. In general, both the overall and the latency analyses provided similar results. Less than a quarter of the matched initiators had 3 or more years of follow-up. Both the current study and the clinical trials had follow-up times that may not allow for full assessment of long-term effects, given the biologically plausible development times for BC.[@b28-dmso-11-791]

The complexity of therapies for patients with diabetes in real-world use settings poses challenges to the design and interpretation of a matched cohort study for BC. The definition of "initiation" required only 6 months with no use of that drug and consequently earlier exposures may not have been captured. In addition to the comparator medications included in this study, patients receive additional ADs and therapies for comorbidities, such as obesity and hypertension. In fact, nearly half of all initiators in each drug cohort had baseline dispensings for metformin (other than metformin initiator cohort). As their diabetes progresses, patients may switch, drop, or add drugs to the initial regimen. Despite the inclusion of many baseline covariates in the PSs to balance the cohorts with respect to these exposures, including insulin and the number of antidiabetic agents, use may differ during the follow-up period leading up to the BC diagnosis.

The first TOD analysis allocated person-time into "current", "recent", and "past" time. While for an acute outcome such as a hypersensitivity reaction, the expectation is that "current" time on the drug would be most critical, for outcomes such as cancer with long latency periods, "past" use is highly relevant, but requires lengthy follow-up. The second type of TOD analysis evaluated the potential for a dose--response relationship through calculation of cumulative exposure to liraglutide. In the present study, the similarity of conclusions for the ITT and TOD approaches lends more weight to the finding of no excess risk for BC among liraglutide initiators.

Both obesity and diabetes are recognized risk factors for BC; however, since all of the patients in the study are on antidiabetic medications, and cohorts were matched on many factors related to obesity, the effect estimates are likely to be unconfounded by these factors.

There are a number of strengths. The cohorts were enumerated via a large administrative claims database. The size and breadth of this database enabled numerous comparator cohorts to which liraglutide could be compared, representing therapies with different mechanisms of action. The cohorts were matched across a wide range of variables, including known risk factors for BC. A validated algorithm was used to identify BC cases, supplemented with claims profiles review to further validate case status. This review process is less resource intensive than medical chart adjudication, allowing for the review of a larger population of patients, and since the review is blinded, clinical interpretation of case status was independent of exposure. Analyses to other plausible sources of bias were performed.

Conclusion
==========

Although the relatively short length of follow-up and the potential for residual confounding by unmeasured factors such as obesity limit the ability to fully assess long-term risk, overall the data appear consistent with no effect of liraglutide on the occurrence of BC.

Supplementary materials
=======================

###### 

Time to diagnosis: liraglutide and all comparators.

###### 

Time to diagnosis: liraglutide and all comparators excluding exenatide.

###### 

Time to diagnosis: liraglutide and exenatide.

###### 

Time to diagnosis: liraglutide and DPP4i.

**Abbreviation:** DPP4i, dipeptidyl peptidase-4 inhibitor.

###### 

Time to diagnosis: liraglutide and metformin.

###### 

Time to diagnosis: liraglutide and sulfonylureas.

###### 

Time to diagnosis: liraglutide and pioglitazone.

###### 

Distribution of breast cancer cases and patients by age group and matched cohorts

              All comparator cohort   Liraglutide cohort                                                                                           
  ----------- ----------------------- -------------------- ------------ ------------ --------- ------------ ------------ ------------ ------------ ---------
  Age group   18--39 (%)              40--49 (%)           50--59 (%)   60--64 (%)   65+ (%)   18--39 (%)   40--49 (%)   50--59 (%)   60--64 (%)   65+ (%)
  Cases       4.3                     25.5                 43.6         14.9         11.7      1.2          16.5         42.4         29.4         10.6
  Patients    14.0                    26.5                 37.4         16.3         5.9       13.8         26.4         37.7         15.9         6.1
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![Identification process and outcome for breast cancer case adjudication\
**Notes:** Numbers in the upper portion of this figure reflect the number of actual women and numbers in the matched section of the figure reflect number of matched initiations, including some women who initiated multiple times.](dmso-11-791Fig1){#f1-dmso-11-791}

![Propensity score matched ITT and TOD analyses for BC.\
**Abbreviations:** ITT, intention-to-treat; TOD, time-on-drug; RR, rate ratio; BC, breast cancer.](dmso-11-791Fig2){#f2-dmso-11-791}

###### 

Baseline descriptive characteristics for all female initiators at the time of their first initiation and matched[a](#tfn1-dmso-11-791){ref-type="table-fn"} initiators (from all initiations)

  Description                                              First initiation at cohort entry   All matched initiators (initial and subsequent initiations)                                                             
  -------------------------------------------------------- ---------------------------------- ------------------------------------------------------------- --------- -------------- -------- -------------- -------- ----------------
  **Demographic**                                                                                                                                                                                                     
  Age, years (median, IQR)                                 52                                 44.0--58.0                                                    51        39.0--59.0     52       44.0--59.0     52       45.0--59.0
  18--39                                                   2,077                              14.5                                                          43,738    25.1           2,475    13.8           2,500    14.0
  40--49                                                   3,815                              26.5                                                          35,763    20.5           4,717    26.4           4,734    26.5
  50--59                                                   5,427                              37.8                                                          52,346    30.0           6,741    37.7           6,690    37.4
  60--64                                                   2,229                              15.5                                                          25,184    14.4           2,849    15.9           2,909    16.3
  65+                                                      825                                5.7                                                           17,526    10.0           1,098    6.1            1,047    5.9
  Race (blacks)                                            2,087                              14.5                                                          27,928    16.0           2,665    14.9           2,606    14.6
  Region                                                                                                                                                                                                              
  Northeast                                                917                                6.4                                                           11,810    6.8            1,115    6.2            1,117    6.2
  Midwest                                                  3,119                              21.7                                                          45,572    26.1           3,969    22.2           4,014    22.4
  South                                                    8,673                              60.3                                                          91,235    52.3           10,693   59.8           10,636   59.5
  West                                                     1,664                              11.6                                                          25,940    14.9           2,103    11.8           2,113    11.8
  Cohort entry (year)                                                                                                                                                                                                 
  2010                                                     3,867                              26.9                                                          56,093    32.1           4,010    22.4           4,010    22.4
  2011                                                     3,304                              23.0                                                          33,615    19.3           4,131    23.1           4,131    23.1
  2012                                                     2,911                              20.3                                                          30,992    17.8           3,936    22.0           3,936    22.0
  2013                                                     2,450                              17.0                                                          27,156    15.6           3,301    18.5           3,301    18.5
  2014                                                     1,841                              12.8                                                          26,701    15.3           2,502    14.0           2,502    14.0
  **Health care utilization**                                                                                                                                                                                         
  Doctor cost (\$) (median, IQR)                           756                                343--1,763                                                    623       266--1,546     762      349--1,767     785      359--1,840
  Medication cost (\$) (median, IQR)                       1,406                              641--2,662                                                    310       71--1,003      1,380    645--2,608     1,255    601--2,304
  Total cost (\$) (median, IQR)                            3,156                              1,656--5,951                                                  1,738     724--4,170     3,125    1,657--5,933   2,977    1,629--5,906
  Number of 3-digit diagnosis codes                                                                                                                                                                                   
  0--5                                                     2,581                              18.0                                                          40,541    23.2           3,145    17.6           3,098    17.3
  6--8                                                     3,028                              21.1                                                          39,112    22.4           3,775    21.1           3,928    22.0
  9--13                                                    4,199                              29.2                                                          48,438    27.7           5,232    29.3           5,181    29.0
  14+                                                      4,565                              31.8                                                          46,466    26.6           5,728    32.0           5,673    31.7
  Number of unique drugs                                                                                                                                                                                              
  0--4                                                     1,463                              10.2                                                          49,773    28.5           1,708    9.6            1,764    9.9
  5--7                                                     3,101                              21.6                                                          51,770    29.7           3,828    21.4           3,875    21.7
  8--10                                                    3,659                              25.5                                                          35,210    20.2           4,640    26.0           4,633    25.9
  11+                                                      6,150                              42.8                                                          37,804    21.7           7,704    43.1           7,608    42.6
  Number of health care visits                                                                                                                                                                                        
  0--1                                                     1,311                              9.1                                                           30,272    17.3           1,577    8.8            1,540    8.6
  2--3                                                     4,281                              29.8                                                          58,732    33.6           5,327    29.8           5,385    30.1
  4--5                                                     3,692                              25.7                                                          38,749    22.2           4,587    25.7           4,629    25.9
  6+                                                       5,089                              35.4                                                          46,804    26.8           6,389    35.7           6,326    35.4
  Any emergency room visit                                 2,849                              19.8                                                          37,331    21.4           3,615    20.2           3,551    19.9
  Any hospitalization                                      654                                4.6                                                           11,660    6.7            851      4.8            812      4.5
  Lab tests (median, IQR)                                  9                                  4.0--15.0                                                     7         3.0--13.0      9        4.0--15.0      9        5.0--15.0
  Number of procedures (median, IQR)                       1                                  0.0--3.0                                                      1         0.0--2.0       1        0.0--3.0       1        0.0--3.0
  Enrollment days (median, IQR)                            514                                332.0--852.0                                                  489       305.0--868.0   607      369.0--996.5   651      374.0--1,038.0
  **Baseline diagnoses and procedures**                                                                                                                                                                               
  Type 1 diabetes                                          302                                2.1                                                           1,163     0.7            306      1.7            257      1.4
  Type 2 diabetes                                          11,603                             80.7                                                          106,681   61.1           14,783   82.7           14,874   83.2
  No diabetes diagnosis                                    2,468                              17.2                                                          66,710    38.2           2,791    15.6           2,749    15.4
  Overweight                                               3,185                              22.2                                                          26,920    15.4           3,984    22.3           4,064    22.7
  Any diabetes-related illness                             1,690                              11.8                                                          9,757     5.6            2,108    11.8           2,179    12.2
  Diabetes-related nephropathy                             468                                3.3                                                           2,801     1.6            598      3.3            608      3.4
  Diabetes-related neuropathy                              1,016                              7.1                                                           5,471     3.1            1,252    7.0            1,314    7.3
  Diabetes-related retinopathy                             408                                2.8                                                           2,422     1.4            496      2.8            522      2.9
  In situ breast carcinoma                                 9                                  0.1                                                           73        0.0            10       0.1            10       0.1
  Benign breast disease                                    294                                2.0                                                           3,473     2.0            349      2.0            367      2.1
  Essential hypertension                                   8,427                              58.6                                                          82,230    47.1           10,660   59.6           10,698   59.8
  Hyperlipidemia                                           8,799                              61.2                                                          77,828    44.6           11,033   61.7           11,068   61.9
  Mammograms                                               3,112                              21.7                                                          32,226    18.5           3,892    21.8           3,883    21.7
  Breast biopsy                                            11                                 0.1                                                           110       0.1            14       0.1            13       0.1
  **Baseline health behaviors**                                                                                                                                                                                       
  Smoking (positive)                                       385                                2.7                                                           5,806     3.3            479      2.7            551      3.1
  Alcohol (positive)                                       24                                 0.2                                                           441       0.3            27       0.2            37       0.2
  **Baseline drug dispensings**                                                                                                                                                                                       
  Baseline tamoxifen (oral only) or aromatase inhibitors   29                                 0.2                                                           700       0.4            35       0.2            42       0.2
  Contraception/hormonal replacement                       2,343                              16.3                                                          28,896    16.6           2,854    16.0           2,786    15.6
  Insulin                                                  3,755                              26.1                                                          14,361    8.2            4,387    24.5           4,321    24.2
  Number of unique antidiabetic drugs                                                                                                                                                                                 
  0                                                        4,763                              33.1                                                          125,192   71.7           5,248    29.4           5,274    29.5
  1                                                        5,309                              36.9                                                          36,074    20.7           6,809    38.1           6,879    38.5
  2+                                                       4,301                              29.9                                                          13,291    7.6            5,823    32.6           5,727    32.0

**Notes:**

Patients may have initiated multiple times during the study period, but are allowed to match only once into each drug cohort pair.

###### 

Study follow-up time[a](#tfn2-dmso-11-791){ref-type="table-fn"} in days for matched[b](#tfn3-dmso-11-791){ref-type="table-fn"} liraglutide/study drug pairs

                                                   Matched pairs (first and subsequent initiations)                            
  ------------------------------------------------ -------------------------------------------------- ----- ------------ ----- ------------
  All comparators                                  17,880                                             526   237--954     527   234--956
  All comparators (excluding exenatide)            17,729                                             531   242--954     527   233--956
  Exenatide                                        9,557                                              574   256--987     566   251--979
  DPP-4i (saxagliptin, sitagliptin, linagliptin)   12,173                                             531   231--942     520   233--939
  Metformin                                        11,934                                             515   238--931     497   220--911
  Glyburide/glipizide/glimepiride                  12,418                                             496   222--870     493   221--897
  Pioglitazone                                     8,009                                              606   261--1,112   611   264--1,120

**Notes:**

Follow-up begins on the day following initiation and continues until end of enrollment, or end of study period (December 31, 2014), whichever comes first.

Patients may have initiated multiple times during the study period, but are allowed to match only once into each drug cohort pair.

**Abbreviation:** DPP-4i, dipeptidyl peptidase-4 inhibitor.

###### 

Time[a](#tfn5-dmso-11-791){ref-type="table-fn"} to BC diagnosis in days for adjudicated BC cases (all first initiations and matched[b](#tfn6-dmso-11-791){ref-type="table-fn"} liraglutide/study drug pairs)

                                                    Matched pairs (first and subsequent initiations)                                                     
  ------------------------------------------------- -------------------------------------------------- ----- ---------- ---- ----- ---------- ---- ----- ----------
  **Unmatched**                                                                                                                                          
  Liraglutide and comparators                       797                                                395   162--718                                    
  Liraglutide                                       76                                                 382   181--641                                    
  **Matched cohorts**                                                                                                                                    
  All comparators                                   721                                                395   161--735   94   361   148--775   85   391   183--667
  All comparators excluding exenatide               691                                                395   159--749   90   396   158--714   81   362   183--628
  Exenatide                                         30                                                 397   192--552   39   412   205--676   56   394   186--710
  DPP-4i (saxagliptin,sitagliptin, linagliptin)     110                                                450   139--762   62   479   172--795   67   339   174--598
  Metformin                                         388                                                405   182--750   52   309   159--639   56   415   168--657
  Sulfonylureas (glyburide/glipizide/glimepiride)   134                                                366   131--669   54   321   111--586   53   332   186--480
  Pioglitazone                                      59                                                 395   162--708   41   421   219--689   53   391   175--598

**Notes:**

Time is from day after index date to BC adjudication-determined diagnosis date.

Patients may have initiated multiple times during the study period, but are allowed to match only once into each drug cohort pair.

**Abbreviations:** DPP-4i*,* dipeptidyl peptidase-4 inhibitor; BC, breast cancer.
